Parkinsonism & related disorders最新文献

{"title":"Early-onset Parkinson's disease, regional and national burden, and its attributable risk factors in 204 countries and regions from 1990 to 2021: Results from the global burden of disease study 2021","authors":"Jiayue Wang ,&nbsp;Nan Cheng ,&nbsp;Zhen Yao ,&nbsp;Jinghan Liu ,&nbsp;Xiaoru Kan ,&nbsp;Zhenliang Hui ,&nbsp;Jun Chen","doi":"10.1016/j.parkreldis.2025.107778","DOIUrl":"10.1016/j.parkreldis.2025.107778","url":null,"abstract":"<div><h3>Background</h3><div>Early-Onset Parkinson's Disease (EOPD), defined as diagnosis before age 40, accounts for 5–10 % of Parkinson's cases and is characterized by slower progression and severe motor and non-motor complications. Its global burden has risen significantly, particularly among younger populations, but comprehensive analyses of trends, disparities, and determinants remain scarce.</div></div><div><h3>Methods</h3><div>EOPD burden was examined in 204 countries from 1990 to 2021 using Global Burden of Disease (GBD) 2021 data. Age-standardized rates (ASR) for incidence, mortality, and disability-adjusted life years (DALYs) were computed. Estimated annual percentage change (EAPC) was used to analyze temporal trends. Associations with the Socio-Demographic Index (SDI) were investigated, and projections were made for future trends up to 2035 using time-series models.</div></div><div><h3>Results</h3><div>Global ASRs for incidence, mortality, and DALYs in 2021 were 0.333, 0.006, and 0.461 per 100,000 population, respectively. Incidence and DALYs increased from 1990 to 2021, while mortality fluctuated. Higher burdens were reported in high-SDI regions due to improved detection and longer survival, whereas low-SDI regions faced underdiagnosis and limited healthcare access. Projections suggest a continued rise in EOPD burden, particularly in the 35–39 age group, by 2035.</div></div><div><h3>Conclusion</h3><div>The increasing worldwide burden of EOPD, along with significant regional and socioeconomic inequalities, underscores the pressing necessity for prompt diagnosis, equitable healthcare access, and specific interventions to address this escalating public health issue.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"134 ","pages":"Article 107778"},"PeriodicalIF":3.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative corneal nerve beading analysis: A novel biomarker for Parkinson's disease progression","authors":"Sasi Yaisawang ,&nbsp;Inturat Attapinan ,&nbsp;Ngamjit Kasetsuwan ,&nbsp;Usanee Reinprayoon ,&nbsp;Krit Pongpirul ,&nbsp;Roongroj Bhidayasiri ,&nbsp;Jirada Sringean","doi":"10.1016/j.parkreldis.2025.107764","DOIUrl":"10.1016/j.parkreldis.2025.107764","url":null,"abstract":"<div><div>This study compared corneal nerve beading between Parkinson's disease (PD) patients and healthy controls. Results showed increases in both density and size of nerve beadings in PD, which correlated with disease severity and duration. Corneal nerve beading demonstrated high sensitivity as a potential biomarker for diagnosing and monitoring PD progression.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"134 ","pages":"Article 107764"},"PeriodicalIF":3.1,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking the role of continuous dopaminergic stimulation in Parkinson disease therapy.","authors":"Peter A LeWitt","doi":"10.1016/j.parkreldis.2025.107354","DOIUrl":"https://doi.org/10.1016/j.parkreldis.2025.107354","url":null,"abstract":"<p><p>This Viewpoint will examine continuous dopaminergic stimulation (CDS), a concept that has long been invoked as the optimal treatment strategy for improving symptomatic control of Parkinson disease (PD) patients experiencing motor fluctuations. The appeal of CDS has always seemed intuitive and is based, in part, on preclinical investigations implicating pulsatile dopaminergic stimulation as causing motor fluctuations and dyskinesia from levodopa (LD) treatment. However, four large-scale randomized controlled clinical trials testing infused drug delivery have demonstrated only partial effectiveness of CDS at reducing daily OFF time. Other clinical trial data has offered evidence that a reduction in OFF time also can be accomplished from targeting sites in motor pathways downstream from the basal ganglia. Neural plasticity and a CNS calcium receptor signaling compound, ophthalmate, may also hold answers to the regulation of OFF time. Finally, insights derived from neural computational modeling of PD motor pathway pharmacology and the involved electrophysiological connections may guide future understanding of motor fluctuations in PD and their management.</p>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":" ","pages":"107354"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18F-FDG PET findings in Parkinson's disease associated to RAB32 S71R variant","authors":"Francesco Cavallieri ,&nbsp;Alessandro Fraternali ,&nbsp;Annachiara Arnone ,&nbsp;Valentina Fioravanti ,&nbsp;Edoardo Monfrini ,&nbsp;Francesca Di Biasio ,&nbsp;Giulia Toschi ,&nbsp;Giulia Di Rauso ,&nbsp;Giacomo Portaro ,&nbsp;Sara Grisanti ,&nbsp;Gaetano Salomone ,&nbsp;Teresa Kleinz ,&nbsp;Paola Mandich ,&nbsp;Jefri J. Paul ,&nbsp;Christian Beetz ,&nbsp;Peter Bauer ,&nbsp;Ji Hyun Ko ,&nbsp;Matteo Bauckneht ,&nbsp;Andrea Melpignano ,&nbsp;Angelina Filice ,&nbsp;Franco Valzania","doi":"10.1016/j.parkreldis.2025.107343","DOIUrl":"10.1016/j.parkreldis.2025.107343","url":null,"abstract":"<div><h3>Objective</h3><div>The RAB32 S71R variant has been linked to autosomal dominant Parkinson's disease (RAB32-PD), sharing common biological mechanisms with the leucine-rich repeat kinase-2 (LRRK2) gene. Measurement of regional differences in glucose metabolism with 18F-fluorodeoxyglucose (FDG) PET may improve the understanding of the neural mechanisms of RAB32-related PD and non-mutated PD (NM-PD). In this brief communication, we compared FDG-PET findings of eight RAB32-PD with a cohort of NM-PD.</div></div><div><h3>Methods</h3><div>Brain FDG-PET study was performed during the ON medication condition under chronic dopaminergic treatment. All images were normalized to a standard FDG-PET template, then a semi‐quantitative analysis was performed on a commercially available fully‐automated post‐processing software (Cortex ID SUITE, GE Healthcare). Clinical assessment included the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the Montreal Cognitive Assessment (MoCA). Continuous variables between groups were compared through the Mann-Whitney test while nominal/ordinal variables through the chi-squared test.</div></div><div><h3>Results</h3><div>Eight RAB32-PD patients (males:3/8; age:65.38 years [±8.73]; disease duration:10.50 years [±5.88]; H&amp;Y:2.81[±1.22]; MDS-UPDRS-III:36.38 [±25.34]; MoCA:24.88[±5.86]) and 19 NM-PD patients (males:11/19; age:60.53 years [±8.00]; disease duration:8.68 years [±5.70]; H&amp;Y:2.39 [±.51]; MDS-UPDRS-III:29.95 [±11.14]; MoCA:24.21 [±6.07]) were included. No statistically significant differences in FDG-PET data and clinical variables were found between RAB32-PD and NM-PD cohorts. In the majority of RAB-32 PD patients a prevalent parietal hypometabolism was observed, similar to previous findings reported in LRRK2-related PD and NM-PD.</div></div><div><h3>Interpretation</h3><div>This study represents the first description of FDG-PET findings in RAB32-PD patients, highlighting a possible similar pattern of hypometabolism with LRRK2- and NM-PD. Additional studies with matched and comparable control cohorts are needed to confirm these preliminary results.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"134 ","pages":"Article 107343"},"PeriodicalIF":3.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response -- letter to the editor: Unraveling the neural signatures: Distinct pallidal patterns in dystonia subtypes.","authors":"Aasef G Shaikh, H A Jinnah, Alexey Sedov","doi":"10.1016/j.parkreldis.2025.107350","DOIUrl":"https://doi.org/10.1016/j.parkreldis.2025.107350","url":null,"abstract":"<p><p>We recognize the need for longitudinal measures and mechanistic understanding of the basis for phenotype to single-neuron correlations. We clarify that pallidal neuron differs across dystonia subtypes. We highlight animal studies showing how cerebellar activity can influence pallidal neuron behavior, supporting the idea of cerebellar activity transmission to the pallidum.</p>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":" ","pages":"107350"},"PeriodicalIF":3.1,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breath hydrogen levels in patients with Parkinson's disease: A pilot cross-sectional study","authors":"Sonja Baltic ,&nbsp;Nikola Todorovic ,&nbsp;Sanela Popovic ,&nbsp;Vladimir Galic ,&nbsp;Marija Semnic ,&nbsp;Sergej M. Ostojic","doi":"10.1016/j.parkreldis.2025.107353","DOIUrl":"10.1016/j.parkreldis.2025.107353","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"133 ","pages":"Article 107353"},"PeriodicalIF":3.1,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in the diagnosis latency of Parkinson's disease in Latin America","authors":"Janvi Ramchandra ,&nbsp;Miguel Inca-Martinez ,&nbsp;Thiago Peixoto Leal ,&nbsp;Henry Mauricio Chaparro-Solano ,&nbsp;Amira Salim ,&nbsp;Emilia M. Gatto ,&nbsp;Natalia González Rojas ,&nbsp;Gustavo Da Prat ,&nbsp;Federico Micheli ,&nbsp;Bruno Lopes Santos-Lobato ,&nbsp;Francisco E.C. Cardoso ,&nbsp;Sarah Camargos ,&nbsp;Grace H. Letro ,&nbsp;Pedro Braga-Neto ,&nbsp;Vitória Maria Torres Peixoto ,&nbsp;Artur F.S. Schuh ,&nbsp;Vitor Tumas ,&nbsp;Manuelina M. Brito ,&nbsp;Vanderci Borges ,&nbsp;Carolina Candeias da Silva ,&nbsp;Ignacio F. Mata","doi":"10.1016/j.parkreldis.2025.107344","DOIUrl":"10.1016/j.parkreldis.2025.107344","url":null,"abstract":"<div><h3>Background</h3><div>Age and sex are known risk factors for Parkinson's Disease (PD), but it remains controversial if there are sex differences in the diagnosis latency. The objective of this study was to examine these sex differences in Latin America.</div></div><div><h3>Methods</h3><div>The Latin American Research Consortium on the Genetics of PD (LARGE-PD) includes PD patients from countries across Latin America who were diagnosed using the UK Brain Bank criteria. Ages at onset (AAO; N = 2,792), diagnosis (AAD; N = 1,416), and calculated diagnosis latency (N = 1,416) were extracted from the LARGE-PD database and compared for both males and females overall, by country, and decade-long age ranges. A cohort was created based on available data for motor sign at onset (N = 492). Regressions examining diagnosis latency as a factor of sex, country, and motor subtype were performed. Two-tailed t-tests at 95 % confidence intervals were used to identify differences in mean AAOs, AADs, and diagnosis latencies between the sexes.</div></div><div><h3>Results</h3><div>Across the LARGE-PD cohort, lower AAD was observed in males. Per country, AAO was lower for males in Mexico and diagnosis latency was shorter for males in Chile. Overall, younger females (≤39) and older males (≥70) are likely to experience longer latencies.</div></div><div><h3>Conclusions</h3><div>Our results suggest that there may be country and age dependent sex differences in AAO, AAD, and diagnosis latency of PD in Latin America. Interestingly, the mean AAO of LARGE-PD is approximately 6 years younger than studies done with European populations. Analyses with additional data are needed to determine the influence of other factors.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"134 ","pages":"Article 107344"},"PeriodicalIF":3.1,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of spinocerebellar ataxia type 8 with clinical manifestations as Parkinson's disease.","authors":"Yi Wang, Ran Ran, Yi Guo, Dunzhu Mima, Lin Wang","doi":"10.1016/j.parkreldis.2025.107352","DOIUrl":"https://doi.org/10.1016/j.parkreldis.2025.107352","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":" ","pages":"107352"},"PeriodicalIF":3.1,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paroxysmal nocturnal dystonia in DNM1L-related syndrome","authors":"Paula Stretavská ,&nbsp;Ján Necpál ,&nbsp;Eva Trúsiková ,&nbsp;Katarína Okáľová ,&nbsp;Sabina Latka ,&nbsp;Robert Jech ,&nbsp;Michael Zech","doi":"10.1016/j.parkreldis.2025.107351","DOIUrl":"10.1016/j.parkreldis.2025.107351","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"133 ","pages":"Article 107351"},"PeriodicalIF":3.1,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143509122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pilot interventional study on feasibility and effectiveness of the CUE1 device in Parkinson's disease","authors":"Viktoria Azoidou ,&nbsp;Kira Rowsell ,&nbsp;Ellen Camboe ,&nbsp;Kamalesh C. Dey ,&nbsp;Alexandra Zirra ,&nbsp;Corrine Quah ,&nbsp;Thomas Boyle ,&nbsp;David Gallagher ,&nbsp;Alastair J. Noyce ,&nbsp;Cristina Simonet","doi":"10.1016/j.parkreldis.2025.107349","DOIUrl":"10.1016/j.parkreldis.2025.107349","url":null,"abstract":"<div><h3>Introduction</h3><div>Current treatments for patients with Parkinson's disease (PwP) can fail to address gait disturbance and falls, which in turn affect quality of life (QoL). The CUE1 device delivers cueing with vibrotactile stimulation showing potential to alleviate motor symptoms and reduce falls based on preliminary user testing results. This study aimed to evaluate the feasibility, safety, and tolerability of CUE1 and its effect on motor and non-motor symptoms in PwP.</div></div><div><h3>Methods</h3><div>PwP used the CUE1 for 9-weeks and were assessed at week 0, 3, 6, and 9 on MDS-UPDRS Part-III, Timed Up and Go (TUG), TUG with dual task (DT), and Functional Gait Assessment (FGA). Patients-reported outcomes were assessed through MDS-UPDRS Part-I, Part-II, and Part-IV.</div></div><div><h3>Results</h3><div>Ten PwP (5 females, age range: 46–80; disease duration: 3–9 years) completed the CUE1 intervention with 100 % compliance and no adverse events. CUE1 comfort and usability were rated highly (80 %). Immediate CUE1 effect was observed on MDS-UPDRS Part-III (45.40 ± 12.22 vs 39.60 ± 11.74, p = 0.008), TUG (11.53 ± 1.92 vs 11.08 ± 1.94, p = 0.022), TUG DT (18.57 ± 5.75 vs 17.61 ± 6.28, p = 0.037) and FGA (16.40 ± 3.86 vs 18.60 ± 3.92, p = 0.007). Cumulative effect was noted on MDS-UPDRS-III (45.40 ± 12.22 vs 27.80 ± 12.32, p = 0.005), FGA (18.60 ± 3.92 vs 23.10 ± 2.85, p &lt; 0.001), TUG DT (18.57 ± 5.75 vs 13.58 ± 7.05, p = 0.031), MDS-UPDRS Part-I (18.60 ± 6.75 vs 12.20 ± 3.68, p = 0.011), MDS-UPDRS Part-II (17.30 ± 7.29 vs 11.90 ± 8.67, p = 0.002), and MDS-UPDRS Part-IV(7.50 ± 3.75 vs 3.40 ± 2.95, p = 0.003).</div></div><div><h3>Conclusion</h3><div>In this unblinded, feasibility study, cueing with vibrotactile stimulation delivered via the CUE1 technology appeared to be a feasible, safe and well tolerated intervention for PwP improving motor and non-motor features.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"133 ","pages":"Article 107349"},"PeriodicalIF":3.1,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143488477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}